ARTICLE | Company News
Neurimmune, ALS TDI deal
December 16, 2013 8:00 AM UTC
Neurimmune and the not-for-profit's Anelixis Therapeutics LLC virtual biotech subsidiary partnered to develop preclinical human antibodies from Neurimmune that target misfolded superoxide dismutase 1...